Compare MMI & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMI | ABCL |
|---|---|---|
| Founded | 1971 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2013 | 2020 |
| Metric | MMI | ABCL |
|---|---|---|
| Price | $29.58 | $3.48 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $29.00 | $7.75 |
| AVG Volume (30 Days) | 189.9K | ★ 5.2M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $751,284,000.00 | $35,325,000.00 |
| Revenue This Year | $11.94 | $16.99 |
| Revenue Next Year | $15.59 | $62.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.74 | 7.17 |
| 52 Week Low | $27.35 | $1.89 |
| 52 Week High | $42.53 | $6.52 |
| Indicator | MMI | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 51.09 | 34.15 |
| Support Level | $28.74 | $3.42 |
| Resistance Level | $30.30 | $3.78 |
| Average True Range (ATR) | 0.76 | 0.22 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 62.33 | 36.45 |
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.